Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Rebecca Shatsky

Breast Oncology · UCSD

View

Dr. Robert Bast

Breast Oncology · MD Anderson Cancer Center

View

Dr. Sara Tolaney

Breast Oncology · Dana-Farber Cancer Institute

View

Dr. Jason Mouabbi

Breast Oncology · MD Anderson Cancer Center

View

Dr. Matthew Kurian

Breast Oncology · St Elizabeth Healthcare

View

Dr. Sarah Premji

Breast Oncology

View

Dr. Roberto Leon-Ferre

Breast Oncology · Mayo Clinic College of Medicine

View

Dr. Nerea Lopetegui-Lia

Breast Oncology · OSUMC

View

Dr. Allison Kurian

Breast Oncology · SU

View

Dr. Minhtri Nguyen

Breast Oncology · Advisor

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms
    BLDr. Bora Lim
    Leading Voice

    Dr. Bora Lim

    Medical Oncology · Breast Oncology
    The University of Texas MD Anderson Cancer Center
    bora

    Research

    Inhibition of MCL-1 and MEK overcomes MEK inhibitor resistance in triple-negative and inflammatory breast cancers

    2025

    Via Molecular Cancer Therapeutics

    Research

    Incidence and risk factors for pneumonitis due to trastuzumab deruxtecan in metastatic breast cancer: a retrospective cohort study

    2025

    Via Breast Cancer Research

    Research

    Bone-Induced HER2 Promotes Secondary Metastasis in HR+/HER2- Breast Cancer

    2025

    Via Cancer Discovery

    Research

    Sickle cell disease induces chromatin introversion and ferroptosis in CD8+ T cells to suppress anti-tumor immunity

    2025

    Via Immunity

    Research

    Misunderstood trial design: randomisation compels comparison

    2025

    Via The Lancet Oncology

    Research

    Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs

    2025

    Via Cancers

    Research

    NF1-depleted ER+ breast cancers are differentially sensitive to CDK4/6 inhibitors

    2025

    Via Science Translational Medicine

    Research

    Case Report: Successful delivery following chemotherapy in a pregnant patient with metastatic SMARCB1-deficient renal medullary carcinoma

    2025

    Via Frontiers in Oncology

    Research

    A phase Ib/II trial of neoadjuvant neratinib added to standard therapy in patients with HER2-positive or HR-positive/HER2-negative inflammatory breast cancer

    2025

    Via Therapeutic Advances in Medical Oncology

    Research

    Incidence and risk factors for pneumonitis due to trastuzumab Deruxtecan in metastatic breast cancer: a retrospective cohort study

    2025

    Via Breast Cancer Research

    Research

    Phase 2 study of neoadjuvant enzalutamide and paclitaxel for luminal androgen receptor-enriched TNBC

    2024

    Via Cell Reports Medicine

    Research

    Additional expression of T-cell engager in clinically tested oncolytic adeno-immunotherapy redirects tumor-infiltrated, irrelevant T cells against cancer cells to enhance antitumor immunity

    2024

    Via Journal for Immunotherapy of Cancer

    Research

    Comprehensive Analysis Identifies Variability in PI3K Pathway Alterations in Triple-Negative Breast Cancer Subtypes

    2024

    Via JCO Precision Oncology

    Research

    Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy

    2024

    Via Clinical Cancer Research

    Research

    Phase 2 study of neoadjuvant enzalutamide and paclitaxel for luminal androgen receptor-enriched TNBC: Trial results and insights into "ARness"

    2024

    Via Cell Reports Medicine